Altimmune Inc (ALT) concluded trading on Wednesday at a closing price of $5.49, with 4.18 million shares of worth about $22.96 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.94% during that period and on June 04, 2025 the price saw a gain of about 1.29%. Currently the company’s common shares owned by public are about 81.11M shares, out of which, 80.26M shares are available for trading.
Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of 1.10%. Year-to-date (YTD), ALT shares are showing a performance of -23.86% which decreased to -26.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.55 but also hit the highest price of $11.16 during that period. The average intraday trading volume for Altimmune Inc shares is 2.53 million. The stock is currently trading -2.18% below its 20-day simple moving average (SMA20), while that difference is up 6.37% for SMA50 and it goes to -16.46% lower than SMA200.
Altimmune Inc (NASDAQ: ALT) currently have 81.11M outstanding shares and institutions hold larger chunk of about 47.37% of that.
The stock has a current market capitalization of $445.28M and its 3Y-monthly beta is at 0.58. It has posted earnings per share of -$1.25 in the same period. It has Quick Ratio of 15.82 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 2.71% while standing at 4.05% over the month.
Stock’s fiscal year EPS is expected to rise by 6.95% while it is estimated to decrease by -1.72% in next year. EPS is likely to shrink at an annualized rate of 2.31% for next 5-years, compared to annual growth of 3.48% made by the stock over the past 5-years.
Coverage by Stifel stated Altimmune Inc (ALT) stock as a Buy in their note to investors on January 08, 2025, suggesting a price target of $18 for the stock. Stock get a Neutral rating from Goldman on January 24, 2024.
